OncoMatch/Clinical Trials/NCT05765877
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
Is NCT05765877 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies WX-0593 Tablets for non-small cell lung cancer(nsclc).
Treatment: WX-0593 Tablets — This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK fusion
ALK-positive
Required: ROS1 fusion
ROS1-positive
Disease stage
Required: Stage IB, IIA, IIB, IIIA (8th American Joint Committee on Cancer TNM edition)
ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer therapy
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug
Cannot have received: ALK inhibitor
Prior treatment with ALK TKI
Cannot have received: ROS1 inhibitor
Prior treatment with ... ROS1 TKI
Cannot have received: radiation therapy
Prior treatment with local radiotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify